Skeletal Muscle Function in Interstitial Lung Disease
Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease
University of British Columbia
40 participants
Aug 7, 2024
INTERVENTIONAL
Conditions
Summary
Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.
Eligibility
Inclusion Criteria12
- Age 40-80 years (inclusive)
- A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses
- Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis
- Appropriate candidate for pulmonary rehabilitation
- minute walk distance 50m or more
- Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air
- Clinically stable for the preceding 6 weeks
- Can fluently read and write in English
- Age 40-80 (inclusive)
- Normal pulmonary function (80-120% predicted)
- No lung or cardiovascular disease
- Can fluently read and write in English
Exclusion Criteria9
- Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)
- Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation
- Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%
- Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program
- Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit
- Significant emphysema (less than 10% volume on HRCT or FEV1/FVC less than 0.70)
- Currently smoking or previously smoked more than 10 pack-years
- Any medical conditions that prevents them for exercising safely
- Cardiac pacemaker or any metal or electronic inside the body
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants breathe 60% oxygen during exercise
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03800017